Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1982 4
1983 4
1984 4
1985 3
1986 15
1987 15
1988 13
1989 10
1990 30
1991 45
1992 33
1993 69
1994 76
1995 74
1996 90
1997 94
1998 84
1999 135
2000 159
2001 183
2002 218
2003 275
2004 270
2005 287
2006 248
2007 290
2008 302
2009 288
2010 346
2011 361
2012 347
2013 323
2014 347
2015 360
2016 302
2017 285
2018 274
2019 274
2020 321
2021 65
Text availability
Article attribute
Article type
Publication date

Search Results

6,099 results
Results by year
Filters applied: . Clear all
Page 1
Fludarabine and neurotoxicity in engineered T-cell therapy.
Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Lowe KL, et al. Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7. Gene Ther. 2018. PMID: 29789639
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cerebral edema. However, subsequent deaths in the JCAR-015 study after removal of fludarabine and improved understanding behind the mech …
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cer …
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Rummel M, et al. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655425 Clinical Trial.
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. ...Thus, 219 patients were included in the per-protocol analysis (114 bendamustine plus rituxim …
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphoma …
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani BN, Mohty M, Nagler A. Saraceni F, et al. J Hematol Oncol. 2019 Apr 25;12(1):44. doi: 10.1186/s13045-019-0727-4. J Hematol Oncol. 2019. PMID: 31023346 Free PMC article.
BACKGROUND: Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with persistent disease. METHODS: We retrospectively compared outcome of fludarabine-treosulfan (FT), thiotepa-busulfa …
BACKGROUND: Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergo …
Oral fludarabine.
Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(21):2317-23. doi: 10.2165/00003495-200363210-00004. Drugs. 2003. PMID: 14524733 Review.
Fludarabine is an antimetabolite antineoplastic agent used in the treatment of various haematological malignancies, particularly B-cell chronic lymphocytic leukaemia (CLL). ...These results were similar to the 48% overall response rate reported in a similar historical cont
Fludarabine is an antimetabolite antineoplastic agent used in the treatment of various haematological malignancies, particularly B-ce
Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.
Langenhorst JB, van Kesteren C, van Maarseveen EM, Dorlo TPC, Nierkens S, Lindemans CA, de Witte MA, van Rhenen A, Raijmakers R, Bierings M, Kuball J, Huitema ADR, Boelens JJ. Langenhorst JB, et al. Blood Adv. 2019 Jul 23;3(14):2179-2187. doi: 10.1182/bloodadvances.2018029421. Blood Adv. 2019. PMID: 31324638 Free PMC article.
Fludarabine is the most frequently used agent in conditioning regimens for allogeneic hematopoietic cell transplantation (HCT). Body surface area-based dosing leads to highly variable fludarabine exposure. We studied the relation between fludarabine exposure
Fludarabine is the most frequently used agent in conditioning regimens for allogeneic hematopoietic cell transplantation (HCT). Body
(18)F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.
Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L. Chantepie S, et al. J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. Epub 2018 Feb 1. J Nucl Med. 2018. PMID: 29419478 Free article. Clinical Trial.
The tumor uptake, biodistribution, and radiation dosimetry of (18)F-fludarabine were evaluated. Six successive partial-body PET scans were acquired for 250 min after an intravenous 4 MBq/kg bolus of (18)F-fludarabine. ...No uptake was observed, whatever the disease …
The tumor uptake, biodistribution, and radiation dosimetry of (18)F-fludarabine were evaluated. Six successive partial-body PET scans …
Fludarabine: a review.
Hood MA, Finley RS. Hood MA, et al. DICP. 1991 May;25(5):518-24. doi: 10.1177/106002809102500512. DICP. 1991. PMID: 2068837 Review.
The new fluorinated adenine analog, fludarabine, has been tested for efficacy in many tumor types over the past ten years. ...Cytarabine is used principally as an antileukemic agent, and vidarabine as an antiviral. Unlike vidarabine, fludarabine is resistant to deac …
The new fluorinated adenine analog, fludarabine, has been tested for efficacy in many tumor types over the past ten years. ...Cytarab …
[18F]Fludarabine-PET in a murine model of multiple myeloma.
Hovhannisyan N, Dhilly M, Fidalgo M, Fillesoye F, Guillouet S, Sola B, Barré L. Hovhannisyan N, et al. PLoS One. 2017 May 4;12(5):e0177125. doi: 10.1371/journal.pone.0177125. eCollection 2017. PLoS One. 2017. PMID: 28472196 Free PMC article.
Myeloma tumour growth was followed using bioluminescence-based imaging (BLI) and characterised by immunohistochemistry (IHC). The tumour specificity of [18F]fludarabine was evaluated and compared to [18F]FDG. RESULTS: The tumoural uptake of [18F]FDG was greater than that o …
Myeloma tumour growth was followed using bioluminescence-based imaging (BLI) and characterised by immunohistochemistry (IHC). The tumour spe …
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
Shah N, Tam C, Seymour JF, Rule S. Shah N, et al. Leuk Lymphoma. 2015 Jun;56(6):1599-610. doi: 10.3109/10428194.2014.963083. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25213181 Review.
The combination of fludarabine, cyclophosphamide and rituximab (FCR) has been widely used in the treatment of lymphoproliferative disorders, and is now considered as the standard first-line therapy for fit, young patients with chronic lymphocytic leukemia (CLL). ...
The combination of fludarabine, cyclophosphamide and rituximab (FCR) has been widely used in the treatment of lymphoproliferative dis …
Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V, Choquet S. Leblond V, et al. Semin Oncol. 2003 Apr;30(2):239-42. doi: 10.1053/sonc.2003.50040. Semin Oncol. 2003. PMID: 12720144 Review.
Response rates to fludarabine in previously treated patients range from 30% to 50% and are highest among patients who are still sensitive to their primary therapy. The responses last from 32 to 41 months. The principal toxicity of fludarabine is myelosuppression. Tr …
Response rates to fludarabine in previously treated patients range from 30% to 50% and are highest among patients who are still sensi …
6,099 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page